Press Releases

PHOENIX, Dec. 9, 2019 /PRNewswire/ -- U-Haul® International is ready to break ground on a multi-million dollar conference and fitness center, which is set to be the showpiece of its ongoing campus expansion in Midtown Phoenix.

KING OF PRUSSIA, Pa., Dec. 9, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that

SYDNEY, Dec. 9, 2019 /PRNewswire/ -- The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, has made yet another high-profile appointment to the Board of member company, GBS Inc., the company has announced. Professor Jonathan Sessler, world-renowned chemist, has been appointed as Director.A bio

TORONTO, Dec. 9, 2019 /PRNewswire/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF)

NEW YORK, Dec. 9, 2019 /PRNewswire/ -- NTT Ltd., a world-leading global technol

ESCONDIDO, Calif., Dec. 9, 2019 /PRNewswire/ -- Marijuana Company of America, Inc.  ("MCOA" or the "Company") (OTCQB: MCOA), an innovative hemp and cannabis corporation, today announced the resignation of Donald J. Steinberg as Chairman of the Board, Chief Executive Officer, and Treasurer."It has been an honor to lead the C

WOODCLIFF LAKE, N.J., Dec. 9, 2019 /PRNewswire/ -- Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore. Of Eisai's 38 scientific posters about FYCOMPA, 23 included convulsive seizure f

SEATTLE, Dec. 9, 2019 /PRNewswire/ -- Xealth, a leader in enabling digital health at scale, today announced its recognition as a finalist for the

First in-human Clinical Phase I study of intratumoural tigilanol tiglate (EBC-46) has been published in The Lancet's EBioMedicine journal; An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans; Promising outcomes attained in patients with a variety of solid tumour types, with a 27% treatment response, including 18% c

INCLINE VILLAGE, Nev., Dec. 9, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced today that it has completed the strategic review process that it initiated in September.  As a result, the Company has decided to halt the execution of its growth strategy, cease additional strategic investments and pursue a formal process t